Jay Powers

Jay has had a remarkable track record of success in drug discovery in the biopharmaceutical industry, spanning a period of nearly 20 years. Most recently, Jay was Vice President of Drug Discovery at Flexus Biosciences and then FLX Bio. During his tenure at Flexus, he oversaw drug design efforts in the IDO Inhibitor program, which was the main driver for the company’s acquisition by BMS in early 2015. Previously, he was Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Jay was involved in the discovery and clinical progression of 7 novel drug candidates in the immunology area, the most advanced of which is currently undergoing Phase 3 evaluation in ANCA-associated renal vasculitis. Prior to joining ChemoCentryx in 2007, Jay was at Tularik and then Amgen (after its acquisition of Tularik in 2004), most recently as Scientific Director in Medicinal Chemistry. Jay began his career in 1996, working in the anti-infectives area at Abbott Laboratories.